Esperion Therapeutics, Inc.(NASDAQ : ESPR)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading ESPR News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.04%||68.55||0.9%||$505.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||5.97%||388.49||2.7%||$332.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.69%||127.78||1.9%||$250.96m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.75%||118.30||1.9%||$235.75m|
|NBIX||Neurocrine Biosciences, Inc.||-0.36%||53.40||5.3%||$114.24m|
|BMRN||BioMarin Pharmaceutical Inc.||-0.40%||95.88||4.5%||$113.09m|
|KITE||Kite Pharma, Inc.||-0.68%||82.08||16.6%||$94.29m|
|A||Agilent Technologies, Inc.||-0.70%||55.04||1.5%||$93.33m|
|SRPT||Sarepta Therapeutics, Inc.||4.44%||36.26||19.8%||$82.73m|
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.